Hallmarks of Treatment Aspects: Parkinson's Disease Throughout Centuries Including l-Dopa.
Deficit of striatal dopamine was first discovered in postmortem brain of patients with Parkinson's disease in 1960. This observation was the starting point for dopamine replacement therapy, and successful introduction of high dose l-dopa therapy in the 1969 revolutionized the treatment of Parkinson's disease. Since then, constant attempts have been made to enhance the efficacy of l-dopa and reduce motor complications by providing more continuous dopamine stimulation. This chapter traces the hallmarks of medical treatments for Parkinson's disease throughout centuries including the first description of antiparkinsonian effects of anticholinergics, the birth of apomorphine in the 1900s, then discovery of l-dopa in the 1960s, and development of dopamine agonists since the 1970s.
['Kim|Hee J|HJ|', 'Jeon|Beom S|BS|', 'Jenner|Peter|P|']
D000978:Antiparkinson Agents D018680:Cholinergic Antagonists D018491:Dopamine Agonists D049673:History, 20th Century D049674:History, 21st Century D006801:Humans D007980:Levodopa D010300:Parkinson Disease
Parkinson's disease l-Dopa Anticholinergics Apomorphine Dopamine agonists Amantadine Levodopa